Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12909926 | 0.69 | CREBBP (0.48) | CA2ALDH1A1CYP2A6CA12CA3 | |
| SCHEMBL29311474 | 0.69 | MAPT (0.35) | ALDH1A1 | |
| SCHEMBL29311492 | 0.65 | CA1 (0.37) | GSK3BCA2ALDH1A1CYP2A6CA12 | |
| SCHEMBL10244720 | 0.65 | CYP2A6 (0.45) | ALDH1A1CYP2A6ELANEPOLBL3MBTL1 | |
| SCHEMBL12890138 | 0.65 | CREBBP (0.42) | ALDH1A1CYP2A6ELANEPOLBCASP3 | |
| SCHEMBL10079094 | 0.64 | KDM4E (0.55) | ALDH1A1POLBMAOAMAOB | |
| SCHEMBL29311487 | 0.62 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL10078773 | 0.62 | CA12 (0.50) | CA2ALDH1A1CA12CA3CA6 | |
| SCHEMBL24258071 | 0.61 | L3MBTL1 (0.53) | ALDH1A1L3MBTL1 | |
| SCHEMBL45942 | 0.59 | CA2 (0.69) | CA2ALDH1A1CYP2A6CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228469-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | GSK3B 130/4885CA2 4099/4885ALDH1A1 3112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.